Linden‐Carmichael et al. (this issue) rightly caution against prematurely drawing
conclusions regarding the safety of consuming alcohol mixed with energy drinks (AMED).
Our aim in conducting a meta‐analysis (Verster et al., 2018) was not to play down
the risks associated with AMED consumption, rather it was to give an objective picture
of the literature on functional consequences of AMED consumption using data available
at the time of conducting the review. Linden‐Carmichael et al. suggest that their
recent diary method paper (Linden‐Carmichael & Lau‐Barraco, 2017) casts doubt on the
conclusions of our meta‐analysis. As the paper in question was, in the authors' words,
“published after Verster and colleagues completed their literature review,” it was
not included. Nevertheless, the paper is a welcome contribution to the AMED literature.
To suggest, however, that this single paper supersedes all previous work in the field
does seem rather premature.
Consuming alcohol in any form, including AMED, carries risks. It is important, however,
that the functional consequences of AMED and alcohol only (AO) consumption are reported
on the basis of empirical, evidence‐based analyses. Our meta‐analysis paper confirms
that, compared with AO consumers, AMED users consume more alcohol and are subject
to more alcohol‐related harms. It is also true that AMED consumers differ significantly
from non‐AMED consumers on a number of other dimensions, e.g., they are significantly
more likely to be male, taller, and use drugs (e.g., De Haan et al., 2012). We have
therefore cautiously suggested that AMED consumption may be, at least partly, one
of several phenotypical manifestations of some other dispositional factor or trait.
One of the advantages of meta‐analysis is that the method captures and synthesizes
the extant literature. In this case, as a secondary aim, we can examine whether the
results of the meta‐analysis are consistent with our hypothesis by focusing on any
differences in between‐subjects and within‐subjects comparisons.
AMED consumers tend to mix alcohol with energy drinks on a minority of drinking occasions
(Verster et al., 2018; Verster, Aufricht, & Alford, 2012). If AMED consumption is
one of several manifestations of some underlying trait, we would predict that AMED
consumers would drink a similar amount of alcohol (and have a similar frequency of
alcohol‐related consequences) when they drink AMED to when they consume AO. Alternatively,
If AMED consumption is causal in producing alcohol‐related harms, then one would predict
that AMED users would drink more (and be subject to more negative alcohol‐related
consequences) on AMED occasions than on AO occasions. Our meta‐analysis (Verster et
al., 2018) shows unequivocally that (a) compared with those who never consume AMED
but consume AO, AMED consumers drink more alcohol and, by extension, engage in more
alcohol‐related harmful behaviors (between‐subjects analysis of N = 6,061 AMED and
N = 14,496 AO consumers in total); (b) compared with when they consume AO, on the
occasions where AMED drinkers co‐consume alcohol and energy drinks, they do not consume
more alcohol and, by the same argument, not engage in more alcohol‐related harmful
behaviors (within‐subjects analysis of N = 3,480 AMED consumers).
This result, which would hold irrespective of who conducted the meta‐analysis, supports
the notion that AMED consumption may be, at least in part, one manifestation of an
underlying trait. This is important because better understanding of the reasons why
certain individuals become AMED consumers (possibly as one of a cluster of harmful
drug and alcohol related behaviors) may help in the early identification of these
individuals in order to instigate preventative measures. An alternative view is that
AMED consumption is causal in producing alcohol‐related harms, so a better strategy
would be to differentially restrict access to AMED over other forms of alcohol. The
meta‐analysis supports the former. This does not preclude the possibility of other
processes, not examined in the meta‐analysis, being differentially associated with
AMED; nor does it mean there should be no further investigation into the possible
harms associated with AMED. Indeed, as we state in the abstract of our paper, “Further
research may be necessary to fully reveal the effects of AMED.” (Verster et al., 2018).
Linden‐Carmichael et al. (this issue) identify possible problems with survey methods,
in particular that they can be subject to recall bias—presumably with this recall
bias differentially affecting memory of AMED over AO occasions. Specifically, this
would require recall bias to result in under‐reporting of harms during AMED but not
AO occasions. No mechanism is put forward for this differential effect, although it
may be that, as AMED consumers tend to drink AO on the majority of occasions, there
is more opportunity to recall AO‐related harms. It is certainly true that such studies
are imperfect, but they can provide useful information for meta‐analyses and reviews.
For example, the same authors' 2014 “qualitative review of psychosocial risk factors”
associated with AMED use concludes that “use of such beverages is associated with
negative consequences including heavy alcohol use, risky sexual and driving behaviors,
as well as other drug use” (Linden & Lau‐Barraco, 2014). Notably, when rallying around
20 surveys to support their contention, the authors did not once mention the possibility
of recall bias.
We concur with Linden‐Carmichael et al. (this issue) that AMED research presents its
own unique problems. Unfortunately, this research area has been undermined to some
degree by selective reporting of the harms associated with AMED. However, we believe
that meta‐analyses can provide useful information that may be complemented and challenged
by single studies but not undermined by them. As an example, Linden‐Carmichael and
Lau‐Barraco (2017) suggest that “one reason for the link between CAB use and alcohol
outcomes may be that caffeine can reduce one's feelings of intoxication without reducing
actual drunkenness” (note that CAB refers to caffeinated alcoholic beverage, including
AMED). The phenomenon of “masking”, the notion that coconsuming caffeine with alcohol
could reduce perceived intoxication while leaving alcohol impairment unaffected is
not supported by the literature. Rather than reference a meta‐analysis (Benson, Verster,
Alford, & Scholey, 2014), which included all subjective intoxication studies, Linden‐Carmichael
and Lau‐Barraco (2017) cite a single study by Marczinski and Fillmore (2006) to support
this contention. They report that Marczinski and Fillmore “found after consuming CABs
as opposed to regular alcohol, participants felt less intoxicated” (p. 882). In fact,
despite an abstract concluding that “subjective measures of intoxication showed that
coadministration of caffeine with alcohol reduced participants' perceptions of alcohol
intoxication compared with administration of alcohol alone” (Marczinski & Fillmore,
2006), this finding is not as clear as stated. The study reported that a lower (2 mg/kg)
dose, equivalent to an average of around 140 mg of caffeine in their sample, reduced
self‐rated alcohol intoxication, whereas a higher (4 mg/kg or 280 mg) dose of caffeine
did not. Further, Marczinski and Fillmore state that “coadministration of 2.0 mg/kg
of caffeine with alcohol significantly lowered beverage ratings [a measure of subjective
intoxication] as compared with alcohol alone, t(11) = 1.77, p = .05” (p. 455). Taken
at face value, a lower but not a higher dose of caffeine had, at most, a marginally
significant effect on perceived intoxication. The picture is further complicated,
however, by a statistical anomaly in the Marczinski and Fillmore (2006) paper, which
has previously been alluded to (Benson et al., 2014; Benson & Scholey, 2014). Their
reported t value of 1.77 with 11 degrees of freedom is associated with a p value of
.052 (one tailed) or .14 (two tailed), so strictly speaking was not significant. It
is unclear why Linden‐Carmichael and Lau‐Barraco (2017) would choose to cite the results
of one of two arms in a single study over a well‐conducted meta‐analysis (or indeed
several papers by Marczinski's group, which did not find a masking effect). It does,
however, illustrate the pitfalls of choosing a single study (or in this case, one
dose from a single study) over a more thorough synthesis of the data. The nature of
meta‐analyses enables more representative findings to emerge and to indicate which
individual studies are outliers.
Unfortunately, this is not simply an academic exercise. Expectancies about the effects
of drugs can affect their outcomes. In an elegant experiment, Fillmore, Roach, and
Rice (2002) showed that when subjects were led to expect that caffeine reversed the
effects of alcohol, the consequence was increased impairment when alcohol was mixed
with caffeine. Thus, falsely suggesting that masking occurs, or that AMED harms exist
if they do not, could have serious real‐world consequences if they are publicized
and believed by AMED users.
There is a dearth of prospective cohort studies comparing AMED and AO effects, and
many of the studies in this field have methodological flaws. Thus, Linden‐Carmichael
et al. (this issue) rightly indicate that their recent diary paper has certain advantages.
For example, their approach allowed drinking patterns and functional consequences
to be captured the next day rather than weeks or months later. This does not mean,
however, that the paper is the last word on AMED‐related harms. There are also a number
of issues regarding data analysis and reporting.
Linden‐Carmichael and Lau‐Barraco (2017) selected N = 122 AMED consumers, described
as “heavy drinking, college student CAB users” (note that CAB = caffeinated alcoholic
beverage, so includes AMED as well as alcohol with other mixers, specifically “Diet
and regular soda.”) Each completed an average of 12.42 entries, allowing, during the
2‐week period, 1,515 opportunities to consume alcohol for the whole sample, of which
389 (25.67%) were taken. The majority (74.04%) of these drinking occasions involved
non‐CAB rather than CAB drinks (presented as 288 vs. 101 in Table 1 of the paper).
Most of the 101 CAB occasions involved non‐AMED beverages (71 vs. 40 in Table 1).
Although, given that 71 + 40 = 111, there may have been 10 occasions when CAB drinker
consumed both. Confusingly, the paper states that of “CAB days, cola‐caffeinated alcoholic
beverages were consumed on 57.43% of CAB days and alcohol mixed with energy drinks
[AMED] were consumed on 39.6% of CAB days.” While the figure for AMED is consistent
with Table 1, those for cola‐caffeinated alcoholic beverages are not. Specifically,
57.43% of 101 is 58, whereas Table 1 reports that soda and alcohol drinks were consumed
on 71 out of 101 (70.3%) of CAB occasions. The reason for this anomaly is unclear;
it may be that the authors have differentiated noncaffeinated soda from caffeinated
mixers although elsewhere the paper states that both diet and regular soda were considered
“cola‐caffeinated mixers” (p. 884).
Forty AMED occasions were recorded over 14 days in 122 AMED consumers. In other words,
the majority of this cohort of “heavy drinking, college student CAB users” did not
consume CAB or AMED over the 14‐day study period. Taking number of diary completions
into account, they consumed AMED on 2.64% of days available to them (extrapolating
these data would translate to nine or 10 AMED occasions in a year).
Unfortunately, the paper does not specify how many individuals contributed to the
40 AMED occasions, which could range from four individuals each consuming AMED on
10 occasions to 40 individuals each consuming AMED once. We did request this information
from the authors, but, at the time of writing this response no data were received.
Linden‐Carmichael and Lau‐Barraco (2017) concluded that there were more alcohol‐related
harms following AMED than AO. Linden‐Carmichael (this issue) suggest that their study
is superior due to their within‐subjects analysis, stating that the “study compared
days in which individuals consumed CABs as opposed to days in which they consumed
other types of alcohol.” Strictly speaking this is not accurate. It would be more
correct to state that the study compared CAB with non‐CAB occasions within a cohort
of CAB users. A more appropriate approach would be to conduct a true within‐subjects
comparison among only those subjects who experienced both AMED and AO occasions within
the 14‐day period. This may be possible because the paper states that there were 50.80%
(N = 62) individuals who consumed both non‐CAB and CAB (although the number of AMED
users within this subset is not specified). Comparing functional consequences of AMED
within the same drinkers (a true within‐subject comparison) over the period of study
would have provided useful information regarding the role of AMED in alcohol harms.
Findings from the Linden‐Carmichael and Lau‐Barraco (2017) study need to be replicated
(perhaps addressing some of the shortcomings outlined above). They do not change the
validity of our meta‐analysis and its outcome that “mixing alcohol with energy drink
does not affect subjective intoxication and seems unlikely to increase total alcohol
consumption, associated risk‐taking behavior, nor other negative alcohol related consequence.”
Taken together, we are pleased to have this opportunity to respond to Linden‐Carmichael
et al. (this issue) and believe that, as concluded in Verster et al. (2018), “Further
research may be necessary to fully reveal the effects of AMED.”
CONFLICT OF INTEREST
The authors have declared no conflict of interest.
DISCLOSURE OF INTERESTS
Chris Alford has undertaken sponsored research or provided consultancy, for a number
of companies and organizations including Airbus Group Industries, Astra, British Aerospace/BAeSystems,
Civil Aviation Authority, Duphar, FarmItalia Carlo Erba, Ford Motor Company, ICI,
Innovate UK, Janssen, LERS Synthélabo, Lilly, Lorex/Searle, Ministry of Defense, Quest
International, Red Bull GmbH, Rhone‐Poulenc Rorer, and Sanofi Aventis. Sarah Benson
has received funding from Red Bull GmbH, Kemin Foods, Sanofi Aventis, and GlaxoSmithKline.
Samuel Benrejeb Godefroy's research activities are funded by the Ministry of Agriculture,
Fisheries, and Food, Government of Quebec, Canada; the Ministry of Science, Technology,
and Innovation, Government of Quebec; Canada's Innovation Foundation; the U.S. Department
of Agriculture Foreign Agriculture Service; r‐Biopharm GmbH; and r‐Biopharm Canada
Inc. Samuel Godefroy acts as an expert advisor for members of the food and beverage
industry, international organizations (the Food and Agriculture Organization of the
United Nations, the United Nations Industrial Development Organization, and the World
Bank), and international food regulators such as the China National Centre for Food
Safety Risk Assessment and consumer organizations such as Food Allergy Canada. Sean
Johnson has undertaken sponsored research for Pfizer, AstraZeneca, Merck, Gilead,
Novartis, Roche, Red Bull GmbH, the Department for Transport, and Road Safety Trust.
Andrew Scholey has received research funding from Abbott Nutriton, Arla Foods, Bayer
Healthcare, Cognis, Cyvex, GlaxoSmithKline, Kemin Foods, Naturex, Nestlé, Martek,
Masterfoods, Red Bull GmbH, Sanofi, Vesrdure Sciences, and Wrigley and has acted as
a consultant/expert advisor to Abbott Nutrition, Barilla, Bayer Healthcare, Danone,
Flordis, GlaxoSmithKline Healthcare, Masterfoods, Martek, Neurobrands, and Wrigley.
Joris Verster has received grants/research support from the Dutch Ministry of Infrastructure
and the Environment, Janssen Research and Development, Nutricia, Takeda, Red Bull,
Sequential and has acted as a consultant for Canadian Beverage Association, Centraal
Bureau Drogisterijbedrijven, Clinilabs, Coleman Frost, Danone, Deenox, Eisai, Janssen,
Jazz, Purdue, Red Bull, Sanofi‐Aventis, Sen‐Jam Pharmaceutical, Sepracor, Takeda,
Transcept, Trimbos Institute, Vital Beverages, and ZBiotics. Red Bull GmbH was not
involved in the preparation of the manuscript.